BlackRock
BCAX

BlackRock’s Bicara Therapeutics BCAX Stock Holding History

BlackRock’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114M Buy
3,848,090
+1,004,383
+35% +$22.4M ﹤0.01% 2149
2026
Q1 		$56.6M Buy
2,843,707
+315,256
+12% +$5.43M ﹤0.01% 2428
2025
Q4 		$42.6M Buy
2,528,451
+216,662
+9% +$3.7M ﹤0.01% 2631
2025
Q3 		$36.5M Buy
2,311,789
+200,469
+9% +$2.24M ﹤0.01% 2711
2025
Q2 		$19.6M Buy
2,111,320
+769,388
+57% +$9.17M ﹤0.01% 3042
2025
Q1 		$17.5M Buy
1,341,932
+80,331
+6% +$1.07M ﹤0.01% 3013
2024
Q4 		$22M Buy
+1,261,601
New +$26.3M ﹤0.01% 2992

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's BCAX Position: Q2 2026 in Review

BlackRock increased its Bicara Therapeutics (BCAX) stake by 35% in Q2 2026, buying an estimated $22.4M and bringing the position to 3,848,090 shares worth $114M. The position accounts for ﹤0.01% of the portfolio, ranked #2149.

BlackRock first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • BlackRock held 3,848,090 shares of Bicara Therapeutics worth $114M as of Q2 2026.
  • BlackRock bought 1,004,383 Bicara Therapeutics shares in Q2 2026, an estimated $22.4M.
  • Bicara Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2149 holding.
  • BlackRock first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.